Results 361 to 370 of about 413,339 (385)
Some of the next articles are maybe not open access.
Doxorubicin (z.B. Doxorubicin „Ebewe“, Adriblastin®)
2006aufgrund zahlreicher Berichte uber Nekrosen erfolgt die Einstufung von Doxorubicin als ...
openaire +2 more sources
Doxorubicin cardiotoxicity in children
The Journal of Pediatrics, 1980To characterize the long-term effects of doxorubicin hydrochloride (Adriamycin) on left ventricular function, a total of 588 echocardiograms were obtained prospectively in 46 children who were treated for malignancy. We found shortening fraction of the left ventricle to be more useful than systolic time intervals for detecting cardiotoxic effects ...
Kwan Yuen Wong +9 more
openaire +3 more sources
Late doxorubicin cardiotoxicity
Anti-Cancer Drugs, 1992The occurrence of late congestive heart failure (CHF) as the first clinical manifestation of doxorubicin-induced cardiac toxicity is unusual in children and very rare in adults. However, subclinical cardiac dysfunction is commonly detected in children years after treatment with doxorubicin containing regimens.
Mordchai Ravid +2 more
openaire +3 more sources
Hypersensitivity Reaction to Doxorubicin
Drug Intelligence & Clinical Pharmacy, 1984A 42-year-old woman with synovial sarcoma developed a skin flare during doxorubicin therapy. With a subsequent dose, erythema, urticaria, and asthma occurred, despite pretreatment with antihistamines. Skin flares occur in about three percent of patients receiving doxorubicin.
openaire +3 more sources
Mitoxantrone: A Replacement for Doxorubicin?
Drug Intelligence & Clinical Pharmacy, 1984Doxorubicin (Adriamycin) is an unquestionably effective anticancer agent for many types of tumors, including advanced breast cancer. However, cardiotoxic effects of the drug have limited its use. Methods of reducing or preventing doxorubicin-induced cardiotoxicity have been suggested, including an investigational doxorubicin analog, mitoxantrone ...
openaire +3 more sources
Doxorubicin Cardiotoxicity and Melphalan
Annals of Internal Medicine, 1981Excerpt To the editor: Doxorubicin and daunorubicin can cause dose-dependent cardiomyopathy in children and adults (1, 2).
openaire +3 more sources
Doxorubicin-Induced Cardiomyopathy
Journal of Pediatric Oncology Nursing, 1994Doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) is one of the most effective chemotherapeutic agents used in the management of pediatric neoplastic disorders during the past 20 years. However, its use has been limited by well-characterized, dose-related cardiac toxicity. Recently, cardiac dysfunction has been noted in pediatric patients who
openaire +3 more sources